The AT1-receptor blocker, candesartan cilexetil significantly reduces the incidence of non-fatal strokes in elderly patients with mild hypertension while maintaining cognitive function.
– Results from the SCOPE* study, examining the effect of antihypertensive treatment in elderly patients with mild hypertension, are presented for the first time today at the joint meeting of the International Society of Hypertension and the European Society of Hypertension, Prague.
These results show a significant 28% risk reduction (p=0.041) in non-fatal strokes in elderly people with mild hypertension – an often untreated group – when treated with the AT1-receptor blocker, candesartan cilexetil, compared to the control group. SCOPE also reported a non-significant trend to reduced risk (11% risk reduction; p= 0.19) in the candesartan cilexetil treatment group, of major CV events; defined as a combined endpoint of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
Lowering blood pressure was associated with maintained cognitive function, as measured by the MMSE (Mini Mental State Examination). There was no significant difference in the risk of heart attacks or cardiovascular death between treatment groups.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!